G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

• Status: Terminated
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving colony-stimulating factors, such as G-CSF, to the donor helps the stem cells move from the bone marrow to the blood so they can be collected and stored.

PURPOSE: This clinical trial is studying how well a G-CSF-treated donor bone marrow transplant works in treating patients with hematologic cancer or noncancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OHSU Knight Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Busulfan; Cyclophosphamide; Cyclosporine; Cyclosporins; Etoposide; Lenograstim; Methotrexate

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of hematologic malignancy or nonmalignancy

• Candidate for matched, related-donor, allogeneic bone marrow transplantation

• Availability of an HLA-matched (6/6) related donor

PATIENT CHARACTERISTICS:

Performance status

• ECOG 0-2 OR

• Karnofsky or Lansky 70-100%

Life expectancy

• At least 12 weeks

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• No significant functional deficit of any major organ

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior stem cell transplantation